Neurocrine Bio. (NBIX) PT Lowered to $123 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $165.89 +0.63%
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on Neurocrine Bio. (NASDAQ: NBIX) to $123.00 (from $136.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Neurocrine Bio. (NBIX) PT Raised to $224 at Guggenheim
- Cantor Fitzgerald Reiterates Overweight Rating on Neurocrine Bio. (NBIX)
- Neurocrine Bio. (NBIX) PT Raised to $190 at RBC Capital
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
